The transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20-30% of primary human breast cancers and that correlates with poor prognosis. We show Znf217 overexpression drives aberrant differentiation and signaling events, promotes increased self-renewal capacity, mesenchymal marker expression, motility and metastasis, and represses an adult tissue stem cell gene signature downregulated in cancers. By in silico screening, we identified candidate therapeutics that at low concentrations inhibit growth of cancer cells expressing high ZNF217. We demonstrate that the nucleoside analog triciribine inhibits ZNF217-induced tumor growth and chemotherapy resistance, and inhibits signaling events (e.g., P-AKT, P-MAPK) in vivo. Our data suggest ZNF217 is a biomarker of poor prognosis and a therapeutic target in breast cancer patients, and triciribine may be part of a personalized treatment strategy in patients overexpressing ZNF217. Since ZNF217 is amplified in numerous cancers, these results have implications for other cancers.
Introduction
In the most aggressive breast tumors, neoplastic cells activate or amplify oncogenes, or inactivate or delete tumor suppressor genes to promote invasive growth and poor prognosis in patients. Amplification of the human chromosomal region 20q13 occurs in 20-30% of primary human breast cancers, as well as in other cancers, and its amplification correlates with poor patient prognosis (1, 2) .
The ZNF217 gene on human 20q13.2 encodes a transcription factor that is overexpressed in all breast tumors and cell lines in which the gene is amplified, as compared to normal mammary tissue and epithelial cells (1, 2) . The ZNF217 protein is a member of the C 2 H 2 family of transcription factors and contains eight predicted Kruppel-like C 2 H 2 zinc finger motifs and a proline-rich region. It is a component of a human histone deacetylase complex (CoREST-HDAC) and is found in complexes with the transcriptional co-repressor C-terminal binding protein (CtBP), the histone demethylases LSD1 (H3K4, H3K9) and KDM5B/JARID1B/PLU-1 (H3K4) and the methyltransferases G9a (H3K9, H3K27) and EZH2 (H3K27) (3) (4) (5) (6) (7) (8) . Its overexpression in human mammary epithelial cells (MECs) overcomes senescence and promotes immortalization accompanied by increased telomerase activity, increased resistance to TGFß-induced growth inhibition and amplification of c-Myc (9) . ZNF217 binds to the promoters of genes involved in differentiation and is repressed following retinoic acid treatment of pluripotent embryonal cells (10).
In this study we investigated whether and how Znf217 promotes tumor progression and poor prognosis using cultured cells, in vivo transplant models 
Results

ZNF217 is Prognostic of Poor Survival in Breast Cancer Patients
Using microarray expression data from primary breast tumors and corresponding clinical data (11, 12), we found that high ZNF217 amplification and expression correlate with shorter overall survival, disease-specific survival and relapse-free survival ( Figures 1A-B , S1A-B). To determine if ZNF217 overexpression overlapped with another poor prognostic subtype, we compared ZNF217 expression levels across patient subtypes (e.g., ER+, ER-, ERBB2/HER2+, ERBB2/HER2-, luminal and basal patient cohorts) and found that ZNF217 expression levels are highest in ER+ tumors and lowest in basal subtype tumors (data not shown).
We next determined if ZNF217 had prognostic value across breast cancer subtypes. We compared survival and ZNF217 expression by univariate analysis across ER+, ER-, HER2+, luminal and basal subtypes. Patients with tumors expressing high ZNF217 consistently had reduced survival compared to patients with tumors expressing lower ZNF217 across multiple breast cancer subtypes ( Figure 1C and data not shown). For example, in a meta-analysis of relapse-free survival across nine published studies that included 858 patients (ER+HER2-LN-) with ZNF217 expression, we found that ZNF217 expression was significantly ZNF217 overexpression promotes malignancy Whitney), and patients with relapse had higher ZNF217 expression. Similarly, patients grouped into the high expression tertile had significantly worse survival than low expression groups. These data show that ZNF217 is prognostic of poor survival in patients by univariate analysis. Moreover, ZNF217 was a better predictor of survival than ER status by multivariate analysis ( Figure S1C ).
Overexpression of Znf217 Accelerates Loss of Adhesion and Increased
Motility in Mouse Mammary Epithelial Cells
To determine the consequences of Znf217 overexpression, we generated mouse mammary epithelial cell lines that overexpressed Znf217 by retroviral and lentiviral infection. Mouse mammary epithelial cell lines (SCp2, NMuMG, EpH4) overexpressing Znf217 had altered motility showing a more scattered phenotype than adherent, clustered control cells (Figures 2A-C , S2A-C). In a wound healing/scratch assay, individual SCp2 cells ( Figure 2D ) and NMuMG cells (data not shown) overexpressing Znf217 showed increased motility, forward extended lamellipodia and independent migration (i.e., separate from other cells) towards the middle of the scratch ( Figure 2D , Movie S1). In contrast, vector-treated cells migrated as a sheet predominantly with a single leading edge. In keeping with the increased motility, cells overexpressing Znf217 reorganized their actin cytoskeleton with reduced cortical actin and increased actin stress fibers ( Figure   2E ) and upregulated EMT markers including Snail1 and Twist ( Figure 2F ). ZNF217 overexpression promotes malignancy ͺ enriched at their promoters in human breast cancer cell lines and tumors (Table   S1 ). Taken together, these results indicate that the early effects of increased ZNF217 expression would lead to premalignant changes of enhanced mammary epithelial migration.
We used gene expression microarrays of the mouse SCp2 MECs overexpressing Znf217 to identify altered processes and molecular targets of Znf217 ( Figure 2G ). In these cells, 176 genes were upregulated and 243 genes downregulated following Znf217 overexpression. We used DAVID software to classify the gene sets with gene ontology (GO) terms (Table S2 ). The GO terms suggested that Znf217 overexpression promoted increased cell motility, decreased epithelial differentiation, increased vasculature development and changes at the membrane.
We also assayed for clonogenicity and transformation potential in vitro.
Znf217 overexpression in NIH3T3 cells stimulated anchorage independent growth in a soft agar assay, with increased number and size of colonies ( Figure   3A -C).
Znf217 Overexpression in Normal Primary Mammary Epithelium Promotes
Increased Mammosphere Formation in Culture
Because we found that Znf217 overexpression in culture promoted increased motility, decreased epithelial marker expression/increased mesenchymal marker expression and increased clonogenicity/transformation potential in vitro, we reasoned that these changes were consistent with a change in differentiation Figure 3D -E).
To determine if Znf217 could promote progenitor cell phenotypes, we overexpressed Znf217 in normal primary MECs and analyzed clonogenicity potential in the mammosphere assay. Primary MECs infected with Znf217-overexpressing lentivirus and grown in serum-free nonadherent culture conditions demonstrated increased self-renewal capacity ( Figure 3F -G).
Gene Expression Analysis of Mammary Epithelial Cells Following Znf217 Overexpression Predicts Changes in Epithelial Proliferation, Cell Adhesion and Motility
We next determined the impact of Znf217 overexpression on global gene expression in normal primary mouse MECs by gene expression microarrays ( Figure 3H ). Primary MECs were infected with a Znf217-overexpressing lentivirus, passaged to expand the population, and confirmed to overexpress
Znf217 by reverse transcription quantitative PCR (rt-qPCR) ( Figure 3I ). In these MECs, 340 genes were upregulated and 401 genes downregulated following Znf217 overexpression ( Figure 3H ). The GO terms classified by DAVID software (Table S2) suggested that Znf217 overexpression altered the gene expression profile of genes involved in cell proliferation, cell adhesion, cell migration, Gprotein coupled receptor signaling pathways and ribosomal function.
Research. Figure 3H , Table S2 ). These genes included a number of TGFß and Wnt pathway genes (Axud1/Csrnp-1, Bcl9l, Bmper, Bmpr2, follistatin, Samd9l, Sfrp1, Tcf4, Tgfß2, Tgfßr3, Wnt5a). We validated selected genes including Wnt5a and Sfrp1 by rt-qPCR ( Figure 3J ). These results are consistent with Znf217 promoting differentiation towards a less differentiated cell-like phenotype via aberrant signaling in the TGFß and Wnt pathways. We also found that ZNF217 was required for cell proliferation ( Figure S2D ).
We also examined epithelial marker expression in our microarray dataset.
We found increased expression of both K17 (myoepithelial marker) and K18 (luminal epithelial marker) expression ( Figure 3H ). Consistent with these results, we found ZNF217 expression levels correlated with expression of K19 and K8/18, genes with ZNF217 enriched at their promoters in human breast cancer cell lines and tumors and with downregulated expression after ZNF217 knockdown in MCF7 cells (Tables S1, S3 ).
Znf217 Overexpression in Primary Mammary Epithelial Cells Represses an
Adult Stem Cell Expression Signature Downregulated in Cancers
Because the aberrant differentiation markers seen both in vivo and in culture suggest that Znf217 may push mammary epithelial cells to a more progenitor cell-like phenotype, we compared our microarray dataset with our previously defined gene expression signature that we found expressed in adult stem cells 
Overexpression of Znf217 Promotes Metastasis
Since metastasis in vivo often is accompanied by increased motility, invasive, Figure 5E ) (19) .
ZNF217 Promotes Resistance to Chemotherapy
Patients with tumors expressing stem cell-like/progenitor cell markers have increased resistance to chemotherapy (20) . We determined if ZNF217 was a We also found that tumors with low ZNF217 expression responded better to treatment (pathological complete response) than did tumors with high ZNF217 expression. In a second dataset, fine needle aspirate samples were collected prior to treatment and used for gene expression (21) . All patients received similar preoperative treatments (paclitaxel and fluorouracil-doxorubicincyclophosphamide). We found ZNF217 expression levels higher in nonresponsive tumors that did not respond to therapy than in tumors that responded ( Figure 6A ). Therefore, ZNF217 is a prognostic predictor of patient outcome in response to chemotherapy.
ZNF217 Levels are Related to Levels of Activated AKT, MAPK and ERBB3
ERBB3 is a direct target of ZNF217 (22) . We found significant correlation between ZNF217 and ERBB3 expression levels in human breast tumors ( Figure   6B ). To determine the mechanism underlying the effects of ZNF217, we analyzed several downstream signaling molecules downstream of ERBB3 in two human breast cancer cell lines (MCF7, ZR-75-1) that express high levels of ZNF217.
Using both wild type cells and cells after knockdown for ZNF217 expression by siRNA, as described previously (22) These data indicate that these pathways are downstream of ZNF217 and that ZNF217 sensitizes cells to HRG.
ZNF217 is a Drug Target for Individualized Therapy
Since ZNF217 is overexpressed in poor prognostic and chemoresistant breast cancer patients, we sought to identify drugs that kill tumor cells overexpressing ZNF217. We first used a candidate approach to determine if AKT pathway inhibitors promoted cell death in a ZNF217-dependent manner, since ZNF217 is required for and promotes AKT activation [ Figure 6C and (23) We next used an in silico screening approach to identify candidate therapeutics that inhibit growth of cancer cells expressing high ZNF217 at low drug concentrations. We determined ZNF217 expression by rt-qPCR in the NCI60 panel of cell lines. We then used a drug dataset from a panel of ~50,000 drugs generated by the NCI Developmental Therapeutics Program (Table S5) .
To determine if ZNF217 contributes to the drug-induced growth inhibition, we assayed cell death of MCF7 cells infected with lentivirus expressing stably integrated scrambled or ZNF217 shRNA knockdown constructs. As proof-ofconcept, we tested bisacodyl, triciribine, nogalamycin and 2E3E for their ability to influence cell death in culture in a ZNF217-dependent manner. Cells expressing Figure 7F) . Interestingly, the parent mammary epithelial cell line HBL100 expresses low levels of adenosine kinase, which is required for the phosphorylation and activation of triciribine in patients. This suggests that ZNF217 may be a sufficiently predictive biomarker of triciribine efficacy, even in patients with low adenosine kinase, if patients are also treated in combination with a drug such as doxorubicin.
Research. 
Discussion
ZNF217 is a Biomarker of Disease Progression and Treatment Response and is a Therapeutic Target Inhibited by Triciribine
In this study we identified ZNF217 as a prognostic biomarker of reduced survival, metastasis and chemoresistance in breast cancer patients. Using both cultured cells and in vivo mouse transplant models, we found that ZNF217 overexpression contributes to multiple aspects of carcinogenesis including increased proliferation/decreased cell death, increased invasiveness, increased motility, immortalization, chemotherapy resistance, metastasis and progenitor cell expansion. Our data demonstrate that Znf217 promotes carcinogenesis by driving a differentiation gene expression signature towards a less differentiated/progenitor state indicative of expanding a multipotent progenitor population.
We identified a panel of drugs that inhibit the growth of cell lines that overexpress ZNF217 and validated two that induced ZNF217-dependent cell death.
Triciribine: a Component of Therapy for Poor Prognostic Breast Cancer Patients
Triciribine is a nucleoside analog and DNA synthesis inhibitor that has been tested in Phase I clinical trials in cancer patients as well as in one Phase II clinical trial in metastatic breast cancer patients (24) (25) (26) (27) 
ZNF217 Reprograms Tumor Cells to Express Luminal and Myoepithelial
Cell Markers
We found that Znf217 promotes phenotypes suggestive of expansion of progenitor cells in vivo and in culture and drives repression of an adult stem cell gene expression signature that is also downregulated in many epithelial cancers.
Consistent with a progenitor phenotype, ZNF217 promotes increased telomerase, resistance to TGFß growth inhibition, amplified c-MYC (9, 37), as well as chemotherapy resistance (23) . That Znf217 may drive a less differentiated gene expression signature is supported by the observation that 
Statistical analysis
Statistical analysis was performed using Prism 4 software (GraphPad Software, 
Accession Numbers
Microarray data were deposited to the NCBI's GEO Repository and are accessible to reviewers through GEO series accession number GSE24727. 
